Liraglutide sustained release microsphere composition and preparation method thereof

A technology of liraglutide and sustained-release microspheres, which is applied in the field of sustained-release microsphere compositions, can solve problems such as maintaining the effective therapeutic concentration of drugs, and achieve the effects of increasing drug loading, ensuring therapeutic effects, and high blood drug concentrations
CN110368376AInactive Publication Date: 2019-10-25浙江美华鼎昌医药科技有限公司
9 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
浙江美华鼎昌医药科技有限公司
Publication Date
2019-10-25
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a liraglutide sustained release microsphere composition and a preparation method thereof. The composition is composed of liraglutide and a glycolide-lactide copolymer. The composition is prepared by adopting a medicine superfine micro power direct packing method. The liraglutide sustained release microsphere prepared through the method has the high medicine carrying amount, and the high blood concentration can be maintained for a long time when the microsphere is released inside the human body to achieve the ideal treatment effect. Meanwhile, the microsphere has the proper grain size, and is suitable for the injection drug delivery route.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a sustained-release microsphere composition, in particular to a liraglutide sustained-release microsphere composition, and a preparation method of the liraglutide sustained-release microsphere composition. Background technique

[0002] Diabetes is a group of metabolic diseases characterized by hyperglycemia. Diabetes is a chronic disease that requires long-term drug treatment. There are different parenteral antidiabetic drugs on the market, including human insulin and human glucagon-like peptide 1 (GLP-1) agonists.

[0003] Liraglutide is a semi-synthetic / totally synthetic GLP-1 analogue. This medicine is used for the adjuvant treatment of type 2 diabetes. Liraglutide is a fatty acylated peptide drug that prevents it from being rapidly degraded in the human body. Its hypoglycemic effect is blood glucose dependent, and it is not easy to cause hypoglycemia in patients.

[0004] However, the metabolic rate of liraglutide in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More